{"id":70813,"date":"2026-07-28T18:46:39","date_gmt":"2026-07-28T10:46:39","guid":{"rendered":"https:\/\/flcube.com\/?p=70813"},"modified":"2026-07-28T18:46:40","modified_gmt":"2026-07-28T10:46:40","slug":"cspcs-albumin-bound-sirolimus-receives-nmpa-breakthrough-therapy-designation-for-rare-pecoma-tumor","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70813","title":{"rendered":"CSPC&#8217;s Albumin-Bound Sirolimus Receives NMPA Breakthrough Therapy Designation for Rare PEComa Tumor"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>CSPC Pharmaceutical Group Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/1093:HKG\">HKG: 1093<\/a>) announced that the <strong>marketing application<\/strong> for its <strong>self-developed Class 2.2 new chemical drug<\/strong>, <strong>Sirolimus (Albumin-Bound) for Injection<\/strong>, has been <strong>accepted by China&#8217;s National Medical Products Administration (NMPA)<\/strong> and simultaneously granted <strong>Breakthrough Therapy Designation<\/strong> and <strong>Priority Review<\/strong> status. The novel formulation is indicated for <strong>unresectable locally advanced or metastatic malignant perivascular epithelioid cell tumor (PEComa)<\/strong>, a rare and aggressive soft tissue sarcoma with limited treatment options.<\/p>\n\n\n\n<h2 id=\"h-regulatory-overview\" class=\"wp-block-heading\">Regulatory Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Sponsor<\/strong><\/td><td>CSPC Pharmaceutical Group Limited (HKG: 1093)<\/td><\/tr><tr><td><strong>Drug Candidate<\/strong><\/td><td>Sirolimus (Albumin-Bound) for Injection<\/td><\/tr><tr><td><strong>Classification<\/strong><\/td><td>Class 2.2 new chemical drug (China NMPA)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Unresectable locally advanced or metastatic malignant PEComa<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>Marketing application accepted<\/td><\/tr><tr><td><strong>Special Designations<\/strong><\/td><td>Breakthrough Therapy Designation + Priority Review<\/td><\/tr><tr><td><strong>Acceptance Date<\/strong><\/td><td>27 Jul 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Active Ingredient:<\/strong> Sirolimus (rapamycin)<\/li>\n\n\n\n<li><strong>Formulation Innovation:<\/strong> Albumin-bound delivery system (enhanced tumor targeting and pharmacokinetics)<\/li>\n\n\n\n<li><strong>Drug Class:<\/strong> Macrolide immunosuppressant<\/li>\n\n\n\n<li><strong>Primary Target:<\/strong> Mammalian target of rapamycin (mTOR) pathway<\/li>\n\n\n\n<li><strong>Mechanism:<\/strong><\/li>\n\n\n\n<li>Binds to immunophilin FKBP12 to form immunosuppressive complex<\/li>\n\n\n\n<li>Blocks mTOR pathway activation<\/li>\n\n\n\n<li>Inhibits cytokine-mediated T-lymphocyte activation and proliferation<\/li>\n\n\n\n<li>Arrests cell cycle transition from G1 to S phase<\/li>\n\n\n\n<li>Downregulates antibody production<\/li>\n\n\n\n<li><strong>Therapeutic Rationale:<\/strong> PEComa tumors frequently exhibit mTOR pathway dysregulation, making them highly susceptible to mTOR inhibition<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-context-malignant-pecoma\" class=\"wp-block-heading\">Clinical Context \u2013 Malignant PEComa<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Clinical Significance<\/th><\/tr><\/thead><tbody><tr><td><strong>Disease Rarity<\/strong><\/td><td>Ultra-rare soft tissue sarcoma (&lt;1% of all sarcomas)<\/td><\/tr><tr><td><strong>Treatment Challenges<\/strong><\/td><td>Often unresectable at diagnosis; limited systemic therapy options<\/td><\/tr><tr><td><strong>Current Standard<\/strong><\/td><td>No approved therapies specifically for PEComa in China<\/td><\/tr><tr><td><strong>mTOR Relevance<\/strong><\/td><td>High frequency of TSC1\/TSC2 mutations leading to mTOR hyperactivation<\/td><\/tr><tr><td><strong>Unmet Need<\/strong><\/td><td>Critical requirement for targeted therapies addressing molecular drivers<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The Breakthrough Therapy Designation reflects both the rarity of PEComa and the compelling rationale for mTOR inhibition in this molecularly defined patient population.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-strategic-implications\" class=\"wp-block-heading\">Market Impact &amp; Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Orphan Oncology Opportunity:<\/strong> Addresses ultra-rare indication with premium pricing potential and limited competition<\/li>\n\n\n\n<li><strong>Regulatory Acceleration:<\/strong> Priority Review and Breakthrough Therapy Designation could reduce approval timeline by <strong>6-12 months<\/strong> compared to standard review<\/li>\n\n\n\n<li><strong>Formulation Innovation:<\/strong> Albumin-bound technology may provide superior efficacy and tolerability compared to conventional sirolimus formulations<\/li>\n\n\n\n<li><strong>mTOR Franchise Expansion:<\/strong> Builds on established clinical validation of mTOR inhibitors in oncology while addressing unmet need in rare tumors<\/li>\n\n\n\n<li><strong>China Leadership:<\/strong> Positions CSPC as pioneer in developing targeted therapies for ultra-rare cancers in China&#8217;s evolving orphan drug landscape<\/li>\n\n\n\n<li><strong>Global Potential:<\/strong> Success in PEComa could support international regulatory filings and establish precedent for albumin-bound sirolimus in other mTOR-driven malignancies<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory pathways, approval timelines, and commercial potential for Sirolimus (Albumin-Bound). Actual results may differ due to risks including regulatory decisions, competitive dynamics, market acceptance, and post-marketing requirements.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026072701168_c.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of 2026072701168_c.\"><\/object><a id=\"wp-block-file--media-2936427d-279d-44aa-8bfb-ed8222595e2a\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026072701168_c.pdf\">2026072701168_c<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2026072701168_c.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-2936427d-279d-44aa-8bfb-ed8222595e2a\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the marketing application for its self-developed Class&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[16,171,855,38],"class_list":["post-70813","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-cspc-pharmaceutical","tag-hkg-1093","tag-market-approval-filings"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>CSPC&#039;s Albumin-Bound Sirolimus Receives NMPA Breakthrough Therapy Designation for Rare PEComa Tumor - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the marketing application for its self-developed Class 2.2 new chemical drug, Sirolimus (Albumin-Bound) for Injection, has been accepted by China&#039;s National Medical Products Administration (NMPA) and simultaneously granted Breakthrough Therapy Designation and Priority Review status. The novel formulation is indicated for unresectable locally advanced or metastatic malignant perivascular epithelioid cell tumor (PEComa), a rare and aggressive soft tissue sarcoma with limited treatment options.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70813\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CSPC&#039;s Albumin-Bound Sirolimus Receives NMPA Breakthrough Therapy Designation for Rare PEComa Tumor\" \/>\n<meta property=\"og:description\" content=\"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the marketing application for its self-developed Class 2.2 new chemical drug, Sirolimus (Albumin-Bound) for Injection, has been accepted by China&#039;s National Medical Products Administration (NMPA) and simultaneously granted Breakthrough Therapy Designation and Priority Review status. The novel formulation is indicated for unresectable locally advanced or metastatic malignant perivascular epithelioid cell tumor (PEComa), a rare and aggressive soft tissue sarcoma with limited treatment options.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70813\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-28T10:46:39+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-28T10:46:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70813#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70813\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"CSPC&#8217;s Albumin-Bound Sirolimus Receives NMPA Breakthrough Therapy Designation for Rare PEComa Tumor\",\"datePublished\":\"2026-07-28T10:46:39+00:00\",\"dateModified\":\"2026-07-28T10:46:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70813\"},\"wordCount\":444,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"CSPC Pharmaceutical\",\"HKG: 1093\",\"Market approval filings\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70813#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70813\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70813\",\"name\":\"CSPC's Albumin-Bound Sirolimus Receives NMPA Breakthrough Therapy Designation for Rare PEComa Tumor - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-28T10:46:39+00:00\",\"dateModified\":\"2026-07-28T10:46:40+00:00\",\"description\":\"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the marketing application for its self-developed Class 2.2 new chemical drug, Sirolimus (Albumin-Bound) for Injection, has been accepted by China's National Medical Products Administration (NMPA) and simultaneously granted Breakthrough Therapy Designation and Priority Review status. The novel formulation is indicated for unresectable locally advanced or metastatic malignant perivascular epithelioid cell tumor (PEComa), a rare and aggressive soft tissue sarcoma with limited treatment options.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70813#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70813\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70813#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CSPC&#8217;s Albumin-Bound Sirolimus Receives NMPA Breakthrough Therapy Designation for Rare PEComa Tumor\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"CSPC's Albumin-Bound Sirolimus Receives NMPA Breakthrough Therapy Designation for Rare PEComa Tumor - Insight, China&#039;s Pharmaceutical Industry","description":"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the marketing application for its self-developed Class 2.2 new chemical drug, Sirolimus (Albumin-Bound) for Injection, has been accepted by China's National Medical Products Administration (NMPA) and simultaneously granted Breakthrough Therapy Designation and Priority Review status. The novel formulation is indicated for unresectable locally advanced or metastatic malignant perivascular epithelioid cell tumor (PEComa), a rare and aggressive soft tissue sarcoma with limited treatment options.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70813","og_locale":"en_US","og_type":"article","og_title":"CSPC's Albumin-Bound Sirolimus Receives NMPA Breakthrough Therapy Designation for Rare PEComa Tumor","og_description":"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the marketing application for its self-developed Class 2.2 new chemical drug, Sirolimus (Albumin-Bound) for Injection, has been accepted by China's National Medical Products Administration (NMPA) and simultaneously granted Breakthrough Therapy Designation and Priority Review status. The novel formulation is indicated for unresectable locally advanced or metastatic malignant perivascular epithelioid cell tumor (PEComa), a rare and aggressive soft tissue sarcoma with limited treatment options.","og_url":"https:\/\/flcube.com\/?p=70813","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-28T10:46:39+00:00","article_modified_time":"2026-07-28T10:46:40+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70813#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70813"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"CSPC&#8217;s Albumin-Bound Sirolimus Receives NMPA Breakthrough Therapy Designation for Rare PEComa Tumor","datePublished":"2026-07-28T10:46:39+00:00","dateModified":"2026-07-28T10:46:40+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70813"},"wordCount":444,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","CSPC Pharmaceutical","HKG: 1093","Market approval filings"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70813#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70813","url":"https:\/\/flcube.com\/?p=70813","name":"CSPC's Albumin-Bound Sirolimus Receives NMPA Breakthrough Therapy Designation for Rare PEComa Tumor - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-28T10:46:39+00:00","dateModified":"2026-07-28T10:46:40+00:00","description":"CSPC Pharmaceutical Group Limited (HKG: 1093) announced that the marketing application for its self-developed Class 2.2 new chemical drug, Sirolimus (Albumin-Bound) for Injection, has been accepted by China's National Medical Products Administration (NMPA) and simultaneously granted Breakthrough Therapy Designation and Priority Review status. The novel formulation is indicated for unresectable locally advanced or metastatic malignant perivascular epithelioid cell tumor (PEComa), a rare and aggressive soft tissue sarcoma with limited treatment options.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70813#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70813"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70813#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"CSPC&#8217;s Albumin-Bound Sirolimus Receives NMPA Breakthrough Therapy Designation for Rare PEComa Tumor"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70813","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70813"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70813\/revisions"}],"predecessor-version":[{"id":70815,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70813\/revisions\/70815"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70813"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70813"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70813"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}